JP2018522564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522564A5 JP2018522564A5 JP2018506197A JP2018506197A JP2018522564A5 JP 2018522564 A5 JP2018522564 A5 JP 2018522564A5 JP 2018506197 A JP2018506197 A JP 2018506197A JP 2018506197 A JP2018506197 A JP 2018506197A JP 2018522564 A5 JP2018522564 A5 JP 2018522564A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- chain variable
- represented
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 210000002865 immune cell Anatomy 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 102000010956 Glypican Human genes 0.000 claims 9
- 108050001154 Glypican Proteins 0.000 claims 9
- 108050007237 Glypican-3 Proteins 0.000 claims 9
- 230000003834 intracellular effect Effects 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 239000003550 marker Substances 0.000 claims 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 7
- 102000009410 Chemokine receptor Human genes 0.000 claims 4
- 108050000299 Chemokine receptor Proteins 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102000003812 Interleukin-15 Human genes 0.000 claims 2
- 108090000172 Interleukin-15 Proteins 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 101150075175 Asgr1 gene Proteins 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100024151 Cadherin-16 Human genes 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 102000004039 Caspase-9 Human genes 0.000 claims 1
- 108090000566 Caspase-9 Proteins 0.000 claims 1
- 102000002029 Claudin Human genes 0.000 claims 1
- 108050009302 Claudin Proteins 0.000 claims 1
- 102100038449 Claudin-6 Human genes 0.000 claims 1
- 108090000229 Claudin-6 Proteins 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 108010055196 EphA2 Receptor Proteins 0.000 claims 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- -1 Her3 Proteins 0.000 claims 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000762246 Homo sapiens Cadherin-16 Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100026720 Interferon beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 102100023123 Mucin-16 Human genes 0.000 claims 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102000040856 WT1 Human genes 0.000 claims 1
- 108700020467 WT1 Proteins 0.000 claims 1
- 101150084041 WT1 gene Proteins 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 108020005243 folate receptor Proteins 0.000 claims 1
- 102000006815 folate receptor Human genes 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 210000001325 yolk sac Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510481235 | 2015-08-03 | ||
| CN201510481235.1 | 2015-08-03 | ||
| PCT/CN2016/092833 WO2017020812A1 (zh) | 2015-08-03 | 2016-08-02 | 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018522564A JP2018522564A (ja) | 2018-08-16 |
| JP2018522564A5 true JP2018522564A5 (enExample) | 2019-09-05 |
| JPWO2017020812A5 JPWO2017020812A5 (enExample) | 2024-05-13 |
| JP7510246B2 JP7510246B2 (ja) | 2024-07-03 |
Family
ID=57942442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506197A Active JP7510246B2 (ja) | 2015-08-03 | 2016-08-02 | 抗グリピカン３抗体およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12168061B2 (enExample) |
| EP (2) | EP3333192B1 (enExample) |
| JP (1) | JP7510246B2 (enExample) |
| KR (1) | KR102777002B1 (enExample) |
| CN (2) | CN106397593B (enExample) |
| AU (1) | AU2016304060B2 (enExample) |
| BR (1) | BR112018002386A8 (enExample) |
| DK (1) | DK3333192T3 (enExample) |
| ES (1) | ES2883240T3 (enExample) |
| IL (1) | IL257324B (enExample) |
| RU (1) | RU2744245C2 (enExample) |
| SG (1) | SG11201800989RA (enExample) |
| WO (1) | WO2017020812A1 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3198010B1 (en) * | 2014-09-26 | 2020-11-04 | Baylor College of Medicine | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
| WO2017159699A1 (en) | 2016-03-15 | 2017-09-21 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
| ES2937699T3 (es) | 2016-04-22 | 2023-03-30 | Crage Medical Co Ltd | Composiciones y métodos de inmunoterapia celular |
| CN108456250B (zh) * | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| US11344578B2 (en) | 2017-04-19 | 2022-05-31 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| CN108853144A (zh) * | 2017-05-16 | 2018-11-23 | 科济生物医药（上海）有限公司 | Toll样受体激动剂与免疫效应细胞的联用 |
| CN108866003A (zh) * | 2017-05-16 | 2018-11-23 | 科济生物医药（上海）有限公司 | 基因工程化的细胞及应用 |
| CN107129536A (zh) * | 2017-05-24 | 2017-09-05 | 广州市拜沃思生物科技有限公司 | 一种双特异性抗体及其制备方法和应用 |
| CN107384949B (zh) * | 2017-06-27 | 2019-01-15 | 闾民 | 表达GPC3嵌合抗原受体的iNKT细胞及制备、应用 |
| CN109385403B (zh) * | 2017-08-04 | 2024-03-08 | 恺兴生命科技(上海)有限公司 | 靶向gpc3的car nk细胞 |
| CN109468278A (zh) * | 2017-09-08 | 2019-03-15 | 科济生物医药（上海）有限公司 | 基因工程化的t细胞及应用 |
| CN109468279A (zh) * | 2017-09-08 | 2019-03-15 | 科济生物医药（上海）有限公司 | 靶向gpc3的免疫效应细胞及其应用 |
| WO2019052562A1 (zh) * | 2017-09-15 | 2019-03-21 | 科济生物医药（上海）有限公司 | Il-4r的融合蛋白及其应用 |
| EP3741861A4 (en) * | 2018-01-19 | 2021-12-08 | Cafa Therapeutics Limited | REGULATED EXPRESSION OF IL12 THROUGH THE SYNNOTCH RECEIVER |
| JP2021512875A (ja) * | 2018-02-02 | 2021-05-20 | カースゲン セラピューティクス カンパニー リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． | 細胞免疫療法の組み合わせ |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| KR20210013013A (ko) | 2018-03-09 | 2021-02-03 | 카르스젠 테라퓨틱스 리미티드 | 종양 치료 방법 및 조성물 |
| EP3789486A4 (en) * | 2018-05-03 | 2022-03-30 | Cafa Therapeutics Limited | Immune effector cell and use thereof |
| CN110438082B (zh) * | 2018-05-04 | 2024-03-08 | 恺兴生命科技(上海)有限公司 | 表达il-21r结合蛋白的免疫效应细胞 |
| CN110468105B (zh) * | 2018-05-09 | 2024-03-22 | 恺兴生命科技(上海)有限公司 | 表达il-18r结合蛋白的免疫效应细胞 |
| CA3100446A1 (en) | 2018-05-15 | 2019-11-21 | Carsgen Therapeutics Co., Ltd. | Genetically engineered cell and application thereof |
| CN108441505B (zh) * | 2018-05-28 | 2023-07-07 | 上海恒润达生生物科技股份有限公司 | 一种靶向ror1的嵌合抗原受体及其用途 |
| CN110577600B (zh) * | 2018-06-07 | 2021-05-04 | 中国科学院上海药物研究所 | 靶向gpc3的抗体-药物偶联物及其制备方法和用途 |
| WO2020020210A1 (zh) | 2018-07-24 | 2020-01-30 | 科济生物医药（上海）有限公司 | 免疫效应细胞治疗肿瘤的方法 |
| CN110760005A (zh) * | 2018-07-25 | 2020-02-07 | 上海细胞治疗集团有限公司 | 一种靶向Glypican-3抗原的嵌合抗原受体修饰T细胞及其用途 |
| CN109021108B (zh) * | 2018-08-27 | 2019-06-25 | 南京医科大学 | 抗gpc3全人源化抗体、其嵌合抗原受体细胞及应用 |
| MX2021005155A (es) * | 2018-11-01 | 2021-09-30 | Shandong New Time Pharmaceutical Co Ltd | Anticuerpo biespecífico y uso del mismo. |
| US20230158071A1 (en) | 2018-12-07 | 2023-05-25 | Crage Medical Co., Limited | Tumor combined immunotherapy |
| JP2022512450A (ja) * | 2018-12-13 | 2022-02-03 | カースゲン セラピューティクス カンパニー リミテッド | Ｇｐｃ３を標的とする免疫エフェクター細胞およびその応用 |
| CN113271953A (zh) | 2019-01-07 | 2021-08-17 | 科济生物医药（上海）有限公司 | 细胞免疫治疗的组合 |
| EP3883971A1 (en) * | 2019-01-22 | 2021-09-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
| CN113490689B (zh) * | 2019-02-01 | 2024-06-04 | 恺兴生命科技(上海)有限公司 | Tcr融合蛋白及表达tcr融合蛋白的细胞 |
| SG11202110390XA (en) * | 2019-03-21 | 2021-10-28 | Agency Science Tech & Res | Composition |
| WO2020219715A1 (en) * | 2019-04-23 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | A dota-binding chimeric antigen receptor for cellular therapy |
| WO2021110095A1 (zh) * | 2019-12-05 | 2021-06-10 | 上海翰森生物医药科技有限公司 | 抗gpc3抗体、其抗原结合片段及其医药用途 |
| CN111187351B (zh) * | 2020-04-14 | 2020-08-04 | 浙江恒驭生物科技有限公司 | 一种肝癌检测试剂盒 |
| CN115298216A (zh) * | 2020-04-20 | 2022-11-04 | 上海翰森生物医药科技有限公司 | 抗体或其抗原结合片段、其制备方法及医药用途 |
| EP4194055A4 (en) | 2020-08-07 | 2025-02-12 | CRAGE medical Co., Limited | MANIPULATED CELLS AND METHODS FOR MANIPULATING CELLS |
| CN114573702A (zh) * | 2020-12-02 | 2022-06-03 | 康诺亚生物医药科技（成都）有限公司 | 一种新型肿瘤衔接器治疗药物的开发和应用 |
| KR20220080381A (ko) * | 2020-12-07 | 2022-06-14 | (주)이노베이션바이오 | Gpc3에 특이적인 항체 및 이의 용도 |
| CN112225822B (zh) * | 2020-12-14 | 2021-03-23 | 北京基因启明生物科技有限公司 | 高扩增、存续能力和杀瘤作用的CAR-iNKT及应用 |
| US20240301085A1 (en) * | 2021-02-10 | 2024-09-12 | Simcere Zaiming Pharmaceutical Co., Ltd. | Humanized gpc3 antibody and application thereof |
| US20240181055A1 (en) | 2021-04-08 | 2024-06-06 | Crage Medical Co., Limited | Cellular immunotherapy use |
| WO2022218375A1 (zh) * | 2021-04-15 | 2022-10-20 | 克莱格医学有限公司 | 嵌合t细胞受体及其应用 |
| CN117460741A (zh) | 2021-06-29 | 2024-01-26 | 科济生物医药（上海）有限公司 | 调控细胞生理活动的嵌合多肽 |
| CN113527500B (zh) * | 2021-07-16 | 2022-09-20 | 蒋小滔 | 一种磷脂酰肌醇蛋白聚糖3的全人源单克隆抗体、其嵌合抗原受体及应用 |
| CN113354737B (zh) * | 2021-07-20 | 2022-11-18 | 广州爱思迈生物医药科技有限公司 | 一种磷脂酰肌醇蛋白聚糖3抗体及其应用 |
| KR20240112375A (ko) * | 2021-08-19 | 2024-07-18 | 아디셋 테라퓨틱스, 인크. | 막 결합된 글리피칸-3의 검출 방법 |
| EP4527465A3 (en) | 2021-10-15 | 2025-07-09 | Concept to Medicine Biotech Co., Ltd. | Anti-glypican 3 antibodies |
| CN114539410B (zh) * | 2022-03-15 | 2023-09-05 | 苏州量化细胞生物科技有限公司 | Cldn18.2结合抗体、探针及在cldn18.2表达细胞的单细胞测序中的应用 |
| CN119013305A (zh) * | 2022-04-24 | 2024-11-22 | 昱言科技(北京)有限公司 | 靶向gpc3的单克隆抗体和包含此抗体的抗体药物缀合物 |
| CN115850492A (zh) * | 2022-08-18 | 2023-03-28 | 武汉生之源生物科技股份有限公司 | 一种抗磷脂酰肌醇蛋白多糖-3的单克隆抗体、多核苷酸及其制备方法和应用 |
| EP4591887A1 (en) | 2022-09-22 | 2025-07-30 | Lepu Biopharma Co., Ltd. | Gpc3 antibody-drug conjugate and use thereof |
| WO2024067764A1 (zh) * | 2022-09-30 | 2024-04-04 | 信立泰(成都)生物技术有限公司 | 抗gpc3单克隆抗体/双特异性抗体或其抗原结合片段及其用途 |
| WO2025097041A1 (en) * | 2023-11-03 | 2025-05-08 | Board Of Regents, The University Of Texas System | Methods for the detection and treatment of resistant cancers co-expressing alpp and/or alpg/alppl2 |
| WO2025159562A1 (ko) * | 2024-01-24 | 2025-07-31 | 국립암센터 | Gpc3에 특이적으로 결합하는 신규 항체 및 이의 용도 |
| WO2025247316A1 (zh) * | 2024-05-30 | 2025-12-04 | 北京剂泰医药科技有限公司 | 针对gpc3的抗体 |
| CN119798446B (zh) * | 2025-01-06 | 2025-09-12 | 百吉生物医药(广州)股份有限公司 | 一种磷脂酰肌醇蛋白聚糖3单域抗体及其应用 |
| CN119823273B (zh) * | 2025-01-08 | 2025-09-12 | 百吉生物医药(广州)股份有限公司 | 一种抗gpc3蛋白纳米抗体及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002315857B2 (en) * | 2001-06-22 | 2007-07-26 | Kaisha, Chugai Seiyaku Kabushiki | Cell proliferation inhibitors containing anti-glypican 3 antibody |
| PT1506406E (pt) * | 2002-05-23 | 2009-06-03 | Sunnybrook Health Sciences Ct | Diagnóstico de carcinoma hepatocelular |
| AU2002338020A1 (en) * | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | Antibody against blood-solubilized n-terminal peptide in gpc3 |
| CN102702353A (zh) | 2004-07-09 | 2012-10-03 | 中外制药株式会社 | 抗-磷脂酰肌醇蛋白聚糖3抗体 |
| AU2005297772B2 (en) * | 2004-10-26 | 2011-06-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having modified sugar chain |
| US20070087005A1 (en) * | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| MX2009001620A (es) | 2006-08-11 | 2009-02-23 | Schering Corp | Anticuerpos para il-17a. |
| HUE028737T2 (en) * | 2007-07-17 | 2017-01-30 | Squibb & Sons Llc | Monoclonal antibodies against glypican-3 |
| CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
| CN101633693A (zh) * | 2009-08-24 | 2010-01-27 | 中国人民解放军第二军医大学 | 一种抗gpc3的单克隆抗体 |
| ES2666550T3 (es) * | 2011-04-19 | 2018-05-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticuerpos monoclonales humanos específicos para glipicano 3 y uso de los mismos |
| US20140322216A1 (en) | 2011-11-08 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| CN102634486B (zh) * | 2012-03-28 | 2014-12-10 | 南方医科大学 | Gpc3单克隆抗体杂交瘤细胞株7d11及其制备方法和应用 |
| CN103833852A (zh) | 2012-11-23 | 2014-06-04 | 上海市肿瘤研究所 | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 |
| TWI693073B (zh) * | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑 |
| CN107460201A (zh) * | 2013-05-08 | 2017-12-12 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| CN118146379B (zh) * | 2016-04-26 | 2025-09-09 | 恺兴生命科技(上海)有限公司 | 一种改善免疫应答细胞功能的方法 |
-
2016
- 2016-08-02 EP EP16832300.4A patent/EP3333192B1/en active Active
- 2016-08-02 RU RU2018105963A patent/RU2744245C2/ru active
- 2016-08-02 US US15/750,271 patent/US12168061B2/en active Active
- 2016-08-02 CN CN201610626384.7A patent/CN106397593B/zh active Active
- 2016-08-02 DK DK16832300.4T patent/DK3333192T3/da active
- 2016-08-02 EP EP21168464.2A patent/EP3889184A1/en not_active Withdrawn
- 2016-08-02 AU AU2016304060A patent/AU2016304060B2/en active Active
- 2016-08-02 IL IL257324A patent/IL257324B/en unknown
- 2016-08-02 JP JP2018506197A patent/JP7510246B2/ja active Active
- 2016-08-02 ES ES16832300T patent/ES2883240T3/es active Active
- 2016-08-02 SG SG11201800989RA patent/SG11201800989RA/en unknown
- 2016-08-02 CN CN201910736574.8A patent/CN111018986B/zh active Active
- 2016-08-02 BR BR112018002386A patent/BR112018002386A8/pt not_active IP Right Cessation
- 2016-08-02 WO PCT/CN2016/092833 patent/WO2017020812A1/zh not_active Ceased
- 2016-08-02 KR KR1020187006248A patent/KR102777002B1/ko active Active
-
2024
- 2024-05-16 US US18/666,163 patent/US20240342305A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522564A5 (enExample) | ||
| JP2018529327A5 (enExample) | ||
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JPWO2017020812A5 (enExample) | ||
| JP2018528786A5 (enExample) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| Tassev et al. | Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor | |
| JP2019525771A5 (enExample) | ||
| US20240342283A1 (en) | ROR1 CAR or ROR1 / CD19 Dual CAR T Cells for the Treatment of Tumors | |
| JP2015527070A5 (enExample) | ||
| JP2018526033A5 (enExample) | ||
| JP2023052263A (ja) | 腫瘍形質導入のための組成物及び方法 | |
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| JP2020508663A (ja) | 癌の治療のための組成物及び方法 | |
| JP2013500715A5 (enExample) | ||
| JPWO2019173324A5 (enExample) | ||
| CN115403671A (zh) | 靶向Claudin18.2的纳米抗体及其用途 | |
| JP2021528382A (ja) | 免疫エフェクター細胞を腫瘍細胞へ誘引する方法及び手段 | |
| CN114763385A (zh) | 靶向ror1的抗体及其用途 | |
| JP2020532281A (ja) | 二重特異性抗ｐｄ−１抗ｔｉｍ３抗体 | |
| França et al. | Progress on phage display technology: tailoring antibodies for cancer immunotherapy | |
| CN104829725A (zh) | 一种双特异性抗体cd133×cd3的构建及应用 | |
| RU2019104896A (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования | |
| JP7365654B2 (ja) | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |